Megan Tesch, MD, Dana Farber Cancer Institute, Boston, MA, comments on the importance of tailoring breast cancer treatment for patients aged 40 years or younger. Increased representation in clinical trials is essential, due to age-related differences in tumor immune microenvironments. Clinicians subsequently need to understand this population’s unique challenges to improve disease management, psychosocial support, and fertility considerations for optimal outcomes. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
